相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature
M. Varenna et al.
REUMATISMO (2013)
Five years of anti-resorptive activity after a single dose of zoledronate - Results from a randomized double-blind placebo-controlled trial
Andrew Grey et al.
BONE (2012)
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study
Gian Luca Forni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome
Ratna Chatterjee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial
Antonio Llombart et al.
CLINICAL BREAST CANCER (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Use of bisphosphonates in the management of postmenopausal osteoporosis
Socrates E. Papapoulos
BISPHOSPHONATES AND OSTEONECROSIS OF THE JAW (2011)
Bone disease and skeletal complications in patients with β thalassemia major
Rachid Haidar et al.
BONE (2011)
Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
Rene Rizzoli et al.
CALCIFIED TISSUE INTERNATIONAL (2011)
Atypical fractures of the femur and bisphosphonate therapy A systematic review of case/case series studies
Andrea Giusti et al.
BONE (2010)
Beta-thalassemia
Renzo Galanello et al.
ORPHANET JOURNAL OF RARE DISEASES (2010)
Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review
M. Mamtani et al.
OSTEOPOROSIS INTERNATIONAL (2010)
The influence of treatment in specialized centers on survival of patients with thalassemia major
Gian Luca Forni et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration
Ersi Voskaridou et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem
Maria G. Vogiatzi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis
Ersi Voskaridou et al.
ACTA HAEMATOLOGICA (2008)
Bisphosphonates: how do they work?
Socrates E. Papapoulos
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia
B. Fung Ellen et al.
BONE (2008)
Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial
Ersi Voskaridou et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: Results of a double-blind, placebo-controlled randomized study
Eugene V. McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia
C. P. Gilfillan et al.
CALCIFIED TISSUE INTERNATIONAL (2006)
Prevalence of fractures among the Thalassemia syndromes in North America
MG Vogiatzi et al.
BONE (2006)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia
E Voskaridou et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle
N Morabito et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis:: Results of a double-blind, placebo-controlled 3-year study
E McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis
P Pennisi et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2003)
Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized placebo-controlled clinical trial with a 2-year open extension
C Brumsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Bisphosphonates in the treatment of thalassemia-induced osteoporosis
N Morabito et al.
OSTEOPOROSIS INTERNATIONAL (2002)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
分享论文
